{"id":"W4401435930","doi":"10.1093/bjd/ljae266.003","title":"603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Ruxolitinib; Adverse effect; Atopic dermatitis; Clinical trial; Janus kinase inhibitor; Internal medicine; Surgery; Pediatrics; Dermatology; Janus kinase; Myelofibrosis; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002111368,0.0006031035,0.00151797,0.000178715,0.0002820179,0.0008665473,0.0004994915,0.001001941,0.002610945],"category_scores_gemma":[0.001144131,0.0002785818,0.001692164,0.0002302769,0.0004346262,0.0005996487,0.0003008411,0.001683717,0.0004006105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005039116,"about_ca_system_score_gemma":0.0005014615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005340587,"about_ca_topic_score_gemma":0.001873731,"domain_scores_codex":[0.9990784,0.0004760593,0.00007228232,0.0001345117,0.0001110668,0.0001276467],"domain_scores_gemma":[0.9991562,0.0002297291,0.0002196906,0.00007971879,0.00006602972,0.0002486518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8279054,0.02487455,0.01616007,0.002810145,0.003932758,0.0004460865,0.0003063502,0.001192069,0.02423806,0.0002226186,0.0036784,0.09423351],"study_design_scores_gemma":[0.7179691,0.2172567,0.0543636,0.000225469,0.002043504,0.0006430093,0.0001235917,0.0009030511,0.003013909,0.0001410853,0.003277306,0.00003976429],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921687,0.004772505,0.0002288453,0.0002274155,0.00006148893,0.0006929141,0.00065108,0.00002751891,0.001169352],"genre_scores_gemma":[0.9952561,0.001636692,0.0004766161,0.0003532484,0.0001115288,0.0006623811,0.0007675571,0.000009070394,0.0007266648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002610945,"threshold_uncertainty_score":0.0111661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02266750183778903,"score_gpt":0.2817145184424843,"score_spread":0.2590470166046953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}